{"doi":"10.2174/157015911795017344","title":"Long-Term Protective Effects of Methamphetamine Preconditioning Against Single-Day Methamphetamine Toxic Challenges","abstract":null,"journal":"Current Neuropharmacology","year":2011,"id":657704,"datarank":0.8581478471865988,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.4087880061535001,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.4087880061535001,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":16,"citers_with_citation_signal":13,"citers_with_endowment":13,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1716893,"name":"B. Ladenheim","orcid":null,"position":1,"is_corresponding":false},{"id":1716895,"name":"M. T. McCoy","orcid":null,"position":2,"is_corresponding":false},{"id":1716897,"name":"G. Beauvais","orcid":null,"position":3,"is_corresponding":false},{"id":1633876,"name":"N. Cai","orcid":null,"position":4,"is_corresponding":false},{"id":1716899,"name":"I. N. Krasnova","orcid":null,"position":5,"is_corresponding":false},{"id":1716900,"name":"J. L. Cadet","orcid":null,"position":6,"is_corresponding":false},{"id":1716891,"name":"A. B. Hodges","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Long-Term Protective Effects of Methamphetamine Preconditioning Against Single-Day Methamphetamine Toxic Challenges","abstract":"Methamphetamine (METH) use is associated with neurotoxic effects which include decreased levels of dopamine (DA), serotonin (5-HT) and their metabolites in the brain. We have shown that escalating METH dosing can protect against METH induced neurotoxicity in rats sacrificed within 24 hours after a toxic METH challenge. The purpose of the current study was to investigate if the protective effects of METH persisted for a long period of time. We also tested if a second challenge with a toxic dose of METH would cause further damage to monoaminergic terminals. Saline-pretreated rats showed significant METH-induced decreases in striatal DA and 5-HT levels in rats sacrificed 2 weeks after the challenge. Rats that received two METH challenges showed no further decreases in striatal DA or 5-HT levels in comparison to the single METH challenge. In contrast, METH-pretreated rats showed significant protection against METH-induced striatal DA and 5-HT depletion. In addition, the METH challenge causes substantial decreases in cortical 5-HT levels which were not further potentiated by a second drug challenge. METH preconditioning provided almost complete protection against METH -induced 5-HT depletion. These results are consistent with the idea that METH pretreatment renders the brain refractory to METH-induced degeneration of brain monoaminergic systems.","is_dataset_classified":null,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21886558","pmcid":"PMC3137197","openalex_id":"https://openalex.org/W1964582928","authors":[],"funders":[],"total_grants":0,"fwci":0.6538,"citation_percentile":0.58865957,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":1},{"year":2014,"count":4},{"year":2015,"count":5},{"year":2017,"count":3},{"year":2019,"count":1},{"year":2021,"count":2},{"year":2022,"count":1},{"year":2025,"count":1}],"oa_status":"bronze","license":"cc-by","oa_locations":[{"url":"http://www.eurekaselect.com/article/18484","host_type":"journal"},{"url":"http://www.eurekaselect.com/article/18484","host_type":"publisher"},{"url":"http://eurekaselect.com/article/download/73508","host_type":"publisher"},{"url":"https://doi.org/10.2174/157015911795017344","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21886558","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3137197","host_type":"repository"},{"url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.350.2890","host_type":""},{"url":"https://europepmc.org/articles/PMC3137197","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC3137197?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Neuroscience and Neuropharmacology Research","Neurotransmitter Receptor Influence on Behavior","Tryptophan and brain disorders"],"mesh_terms":[],"keywords":["Meth-","Methamphetamine","Monoaminergic","Neurotoxicity","Pharmacology","Monoamine neurotransmitter","Chemistry","Dopamine","Serotonin","Medicine","Toxicity","Internal medicine","Biochemistry","Striatum","Preconditioning."],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T02:05:20.814372Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}